Back to Main

Faculty Detail    
Name DAVID G WARNOCK
 
Campus Address ZRB 636 Zip 0007
Phone 205-934-9509
E-mail dwarnock@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Nephrology Professor
Center  Arthritis & Musculoskeletal Diseases Center  Arthritis & Musculoskeletal Diseases Center Professor
Center  Center for Metabolic Bone Disease  Center for Metabolic Bone Disease Professor
Center  Cystic Fibrosis Research Center  Cystic Fibrosis Research Center Professor
Center  Medicine  Nephrology Res & Trng Ctr Professor
Center  Office of Program Planning & Education Research  Office of Human Res Professor

Graduate Biomedical Sciences Affiliations
Integrative Biomedical Sciences 
Medical Scientist Training Program 

Biographical Sketch 
David G. Warnock, MD is the Director of the Division of Nephrology and Professor of Medicine and Physiology at the University of Alabama at Birmingham. He graduated from the University of California at Berkeley and received his MD degree from the University of California, San Francisco. His clinical training was completed at the University of California, San Francisco, including a 1 year research fellowship with Isidore Edelman, MD in the Cardiovascular Research Institute. Following a fellowship with Maurice Burg, MD at the NIH, Dr. Warnock returned to UCSF as a faculty member. He served as the Section Chief at the San Francisco VA Medical Center during the last 5 years of his appointment at UCSF. Following a sabbatical with Bernard Rossier, MD at the Institute of Pharmacology in Lausanne, Switzerland, Dr. Warnock was recruited to UAB as the Director of Nephrology in 1988.

Since May 1, 2005, Dr. Warnock has also served at the Director of the Office of Human Research at UAB

Dr. Warnock’s research interests include acid-base physiology, sodium transport mechanisms, chronic kidney disease, and inherited renal diseases. He is a member of the American Society for Clinical Investigation, American Association of Physicians, American Physiologic Society, ASN, NFK and ISN. He is currently serving as the President of the National Kidney Foundation.

Society Memberships
Organization Name Position Held Org Link
American Association of Physicians     
American Society of Clinical Investigation     
National Kidney Foundation  President  www.kidney.org 

Research/Clinical Interest
Title
Renal REGARDS, Fabry Registry, Inherited Disease of Electrolyte Transport
Description
My focus is on the factors, genetic and environmental that contribute to hypertension and chronic kidney disease. The spectrum extends from basic studies of salt and water transport systems to population based studies of the prevalence of CKD and the association with stroke and heart disease. We currently have an approved ancillary study of the REGARDS project; a prospective cohort evaluation of 30,000 participants > 45 yrs of age to examine the effects of anemia and chronic kidney disease on the incidence of stroke and heart disease. Another are focuses on inherited disorders of renal function, with a current emphasis on the renal manifestations of Fabry disease. Over 40 patients with Fabry disease have been identified in Alabama and approximately 20 of them have been started on Enzyme Replacement Therapy.

Selected Publications 
Publication PUBMEDID
Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, et al. Related Articles, Links Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994 Nov 4;79(3):407-14.
 
7954808 
Warnock DG. Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens. 2005 Mar;14(2):87-95.   15687833 
Warnock DG. Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease.
Kidney Int Suppl. 2004 Nov;(92):S121-3. Review.  
15485405 
Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule.
Am J Physiol Renal Physiol. 2004 Oct;287(4):F593-601. Review.
 
15345493 
Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG; Ferrlecit Publication Committee.
Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant. 2004 Jun;19(6):1576-80. Epub 2004 Mar 19.
 
15034152  
Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003 Sep;115(4):291-7.
 
12967694 
Komlosi P, Fuson AL, Fintha A, Peti-Peterdi J, Rosivall L, Warnock DG, Bell PD. Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension. 2003 Aug;42(2):195-9. Epub 2003 Jun 30.   12835330  
Warnock DG. Renal genetic disorders related to K+ and Mg2+.
Annu Rev Physiol. 2002;64:845-76. Review.
 
11826290 
Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG.
Genetic disorders of renal electrolyte transport.
N Engl J Med. 1999 Apr 15;340(15):1177-87. Review.  
10202170 
Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-Dependent Associations between Indices of Iron Store and Mortality in Hemodialysis Patients. J Am Soc Nephrol. 2005 Jul 20; e-Publish  16033854 

Keywords
Renal REGARDS, Fabry Registry, Inherited Disease of Electrolyte Transport, Chronic Kidney Disease